PubRank

A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)

Clinical Trial ID NCT01441193

PubWeight™ 5.38‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01441193

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010 1.13
2 Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006 1.12
3 Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009 0.97
4 The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 2009 0.95
5 Challenges in HIV Vaccine Research for Treatment and Prevention. Front Immunol 2014 0.93
6 Controlling the HIV/AIDS epidemic: current status and global challenges. Front Immunol 2012 0.92
7 The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology 2014 0.92
8 HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One 2012 0.91
9 HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial. Retrovirology 2015 0.89
10 Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C. Microbes Infect 2005 0.88
11 Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate. Rev Recent Clin Trials 2009 0.87
12 HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. Int Rev Immunol 2009 0.85
13 Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin. Vaccine 2008 0.82
14 Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant DeltaV2 Env. Microbes Infect 2005 0.81
15 Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine. Expert Opin Biol Ther 2015 0.79
Next 100